Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Beam Therapeutics Inc Logo

Combined Holdings of Beam Therapeutics (BEAM) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
April 14, 2022BUY38.691k0.0171%ARKK
April 14, 2022BUY13.409k0.0193%ARKG
April 13, 2022BUY7.426k0.0035%ARKK
April 13, 2022BUY2.574k0.0038%ARKG
April 11, 2022BUY12.538k0.0055%ARKK

Key Statistics

Upcoming EarningsSee Full Calendar
DateAugust 08, 2022(Est)Revenue
Expected$8.39m
Actual▫️
EPS
Expected-$1.08
Actual▫️
🕵🏼Found In🏷Last Price
ARKGARKK$39.79
⚖️Weighting🧢Market Cap
2.19%$2.80b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
1346.39
💳ARK Estimated Cost Average🌏Country
$83.03 - ARKG$84.55 - ARKK
🇺🇸United States
🎫ARK Ownership Percent
12.35%
Description
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Website
beamtx.com

Research Notes and Commentary for BEAM